Prospective Phase II Trial of Cemiplimab Plus Gemcitabine in SWItch/Sucrose Nonfermentable-Altered Metastatic Pancreatic Ductal Adenocarcinoma
JCO Oncology Advances · 2026-07 · 3 (3)
DOI: 10.1200/oa-26-00074 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-07. Verfasst von Shawn A. Abeynaike und 8 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Abeynaike, S. A., Alexander, R. V., Snider, C. A., Park, I. H., Kato, S., Kurzrock, R., Hargreaves, D. C., Messer, K. S., & Botta, G. P. (2026). Prospective Phase II Trial of Cemiplimab Plus Gemcitabine in SWItch/Sucrose Nonfermentable-Altered Metastatic Pancreatic Ductal Adenocarcinoma. JCO Oncology Advances, 3(3). https://doi.org/10.1200/oa-26-00074
Vancouver
Abeynaike SA, Alexander RV, Snider CA, Park IH, Kato S, Kurzrock R, et al. Prospective Phase II Trial of Cemiplimab Plus Gemcitabine in SWItch/Sucrose Nonfermentable-Altered Metastatic Pancreatic Ductal Adenocarcinoma. JCO Oncology Advances. 2026;3(3). doi:10.1200/oa-26-00074
BibTeX
@article{Abeynaike2026,
author = {Abeynaike, Shawn A. and Alexander, Roberta Vezza and Snider, Christina A. and Park, In Hwan and Kato, Shumei and Kurzrock, Razelle and Hargreaves, Diana C. and Messer, Karen S. and Botta, Gregory P.},
title = {Prospective Phase II Trial of Cemiplimab Plus Gemcitabine in SWItch/Sucrose Nonfermentable-Altered Metastatic Pancreatic Ductal Adenocarcinoma},
journal = {JCO Oncology Advances},
year = {2026},
volume = {3},
number = {3},
doi = {10.1200/oa-26-00074}
}
EUVIMED